智翔金泰公告，公司的泰利奇拜单抗注射液（GR1802注射液）用于成人中、重度特应性皮炎适应症III期临床试验达到了主要终点指标，公司向国家药品监督管理局（NMPA）药品审评中心（CDE）提交了该适应症的新药上市申请并获得受理。截至本公告披露日，泰利奇拜单抗注射液（GR1802注射液）同靶点药物仅有两款在国内获批上市。
智翔金泰公告，公司的泰利奇拜单抗注射液（GR1802注射液）用于成人中、重度特应性皮炎适应症III期临床试验达到了主要终点指标，公司向国家药品监督管理局（NMPA）药品审评中心（CDE）提交了该适应症的新药上市申请并获得受理。截至本公告披露日，泰利奇拜单抗注射液（GR1802注射液）同靶点药物仅有两款在国内获批上市。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.